Immunic Inc. (IMUX)
IMUX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IMUX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001280776 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $132.0M cash; operating cash flow -$24.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 15,880,822 (2026-11-06); 120,284,724 a year earlier; 45,145,383 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2026-04-27 | Source 2026-04-27 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-04-02 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-06 |
| Auditor | Baker Tilly US, LLP, Minneapolis, Minnesota, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$42.3M | -$28.4M | $132.0M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | Not filed | -$34.1M | -$31.0M | $155.1M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q1 2026 2026-03-31 | Not filed | -$32.6M | -$17.3M | $186.6M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q4 2025 2025-12-31 | Not filed | -$19.3M | -$19.3M | $15.5M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | Not filed | -$25.6M | -$20.1M | $35.1M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$26.8M | -$24.6M | $55.3M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q1 2025 2025-03-31 | Not filed | -$25.5M | -$21.8M | $14.3M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q4 2024 2024-12-31 | Not filed | -$25.2M | -$23.0M | $35.7M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-04-02 |
| Latest annual report | 10-K/A | 2026-04-22 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-05-29 |
Source: SEC EDGAR submissions feed, 837 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.0% |
| 1 month | +9.1% |
| 3 months | -54.6% |
| Year to date | +40.8% |
| 1 year | +5.5% |
| From 52-week high | -55.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PDSB | PDS Biotechnology Corporation | $0.9241 | +5.90% | $113.4M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
| CATX | Perspective Therapeutics Inc. | $0.9238 | -2.05% | $111.6M |
| OKUR | OnKure Therapeutics Inc. | $2.75 | +4.56% | $111.4M |
| NERV | Minerva Neurosciences Inc | $2.20 | -4.35% | $109.6M |
| SPRB | Spruce Biosciences Inc. | $42.25 | -2.45% | $121.4M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier